دورية أكاديمية
Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative
| العنوان: | Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative |
|---|---|
| المؤلفون: | Bosch, Francesc, Navarro, Blanca, Crespo, Marta, Alcoceba, Miguel, Bravo Sánchez, Julio, Tazón‐Vega, Bárbara, Serrano, Alicia, García-Alvarez, María, González Serrano, Lydia, Alonso-Torres, Pablo, Villanueva, Miguel, Loriente, Cristina, Abrisqueta, Pau, Peiró, Manel, García-Marco, José A., González, Marcos, Terol, María José |
| المساهمون: | Janssen Biotech, Johnson and Johnson Pharmaceutical Research and Development, Ministerio de Economía y Competitividad (España) |
| بيانات النشر: | Springer Nature |
| سنة النشر: | 2021 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | CLL, IGHV mutational status, TP53 gene mutations, Laboratory network |
| الوصف: | © The Author(s) 2021. ; Among the different biomarkers predicting response in chronic lymphocytic leukemia (CLL), the most influential parameters are the mutational status of the IGHV genes and the presence of TP53 gene disruptions. Nevertheless, these important assessments are not readily available in most centers dealing with CLL patients. To provide this molecular testing across the country, the Spanish Cooperative Group on CLL (GELLC) established a network of four analytical reference centers. A total of 2153 samples from 256 centers were analyzed over a period of 30 months. In 9% of the patients, we found pathological mutations in the TP53 gene, whereas 48.96% were classified as IGHV unmutated. Results of the satisfaction survey of the program showed a Net Promoter Score of 85.15. Building a national network for molecular testing in CLL allowed the CLL population a broad access to complex biomarkers analysis that should translate into a more accurate and informed therapeutic decision-making. ; This work was supported in part by Janssen Pharmaceutical Companies of Johnson & Johnson. MC holds a contract from Ministerio de Ciencia, Innovación y Universidades (RYC-2012-12018). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 0939-5555 1432-0584 |
| العلاقة: | #PLACEHOLDER_PARENT_METADATA_VALUE#; info:eu-repo/grantAgreement/MINECO//RYC-2012-12018/ES/RYC-2012-12018/; Publisher's version; http://dx.doi.org/10.1007/s00277-020-04331-9Test; Sí; Annals of Hematology 100: 825-830 (2021); http://hdl.handle.net/10261/261123Test; http://dx.doi.org/10.13039/100005565Test; http://dx.doi.org/10.13039/501100003329Test |
| DOI: | 10.1007/s00277-020-04331-9 |
| DOI: | 10.13039/100005565 |
| DOI: | 10.13039/501100003329 |
| الإتاحة: | https://doi.org/10.1007/s00277-020-04331-9Test https://doi.org/10.13039/100005565Test https://doi.org/10.13039/501100003329Test http://hdl.handle.net/10261/261123Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.3B1D61F |
| قاعدة البيانات: | BASE |
| تدمد: | 09395555 14320584 |
|---|---|
| DOI: | 10.1007/s00277-020-04331-9 |